The estimated Net Worth of A. Charlene Sullivan is at least 164 千$ dollars as of 17 August 2012. A Sullivan owns over 10,000 units of Basis Global Technologies Inc stock worth over 164,400$ and over the last 14 years A sold BASI stock worth over 0$.
Sign up
A Sullivan BASI stock SEC Form 4 insiders trading
A has made over 1 trades of the Basis Global Technologies Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently A bought 10,000 units of BASI stock worth 12,600$ on 17 August 2012.
The largest trade A's ever made was buying 10,000 units of Basis Global Technologies Inc stock on 17 August 2012 worth over 12,600$. On average, A trades about 5,000 units every 0 days since 2010. As of 17 August 2012 A still owns at least 10,000 units of Basis Global Technologies Inc stock.
You can see the complete history of A Sullivan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's A Sullivan's mailing address?
A's mailing address filed with the SEC is 2701 KENT AVENUE, , WEST LAFAYETTE, IN, 47906.
Insiders trading at Basis Global Technologies Inc
Over the last 21 years, insiders at Basis Global Technologies Inc have traded over 266,443$ worth of Basis Global Technologies Inc stock and bought 540,162 units worth 1,698,287$ . The most active insiders traders include Jacqueline M Lemke、Robert Jr. Leasure、William D Pitchford. On average, Basis Global Technologies Inc executives and independent directors trade stock every 65 days with the average trade being worth of 128,544$. The most recent stock trade was executed by Beth Taylor on 5 March 2021, trading 5,000 units of BASI stock currently worth 88,500$.
What does Basis Global Technologies Inc's logo look like?
Complete history of A Sullivan stock trades at Basis Global Technologies Inc
Basis Global Technologies Inc executives and stock owners
Basis Global Technologies Inc executives and other stock owners filed with the SEC include:
-
Wendy Perrow,
Independent Director -
R. Matthew Neff,
Independent Director -
Richard Johnson,
Independent Director -
Joseph Flynn,
Chief Commercial Officer -
John Sagartz,
Chief Strategy Officer, Director -
Connie Dougherty,
Vice President - Business Development -
I.M. Grossi,
Vice President - Toxicology -
Philip Downing,
Vice President - Preclinical Services -
Andrew Alexander,
Vice President - Pharmacology and Toxicology Operations -
Michael Baim,
Vice President - Bioanalytical Operations -
Beth Taylor,
Chief Financial Officer, Vice President - Finance -
Robert Leasure,
President, Chief Executive Officer, Director -
Gregory Davis,
Interim Chairman of the Board -
Jill Blumhoff,
VP, Finance & CFO -
John P Devine,
VP--Toxicology -
James Sevall Bourdage,
VP, Bioanalytical Services -
Jacqueline M Lemke,
CFO & Vice President--Finance -
Jeffrey Potrzebowski,
VP, Finance & CFO -
John Gregory Beattie,
Chief Operating Officer -
Peterkissinger Candice B Ki...,
-
Daniel Thomas Oakley,
Chief Operating Officer -
Kimberly L Sagartz,
10% owner -
Chrysalis, Llc Sw,
10% owner -
Lori Payne,
VP Bioanalytical Services -
Larry Steven Boulet,
Director -
David W Crabb,
Director -
John B. Landis,
Director -
David L Omachinski,
Director -
Anthony S Chilton,
COO, Scientific Studies -
A. Charlene Sullivan,
Director -
Alberto F Jr Hidalgo,
VP, Bus. Development & Mrkting -
Leslie B Daniels,
Director -
Kathleen Hodges,
Vice President of Quality -
Lina L Reeves Kerner,
V.P. - Human Resources -
Richard M Shepperd,
President & Chief Exec. Off. -
Ronald E Shoup,
Chief Operating Officer -
Craig S Bruntlett,
Sr. V.P. International Sales -
Jon Brewer,
VP Sales/Marketing -
William E Baitinger,
Director -
Candice B Kissinger,
Vice President -
Margaret B Mcclure,
Dir, Pharmaceutical Lab. Div. -
Michael R Cox,
V.P. Finance, CFO -
Emilio Cordova,
V.P. of Business Development -
Edward Chait,
Executive Vice President -
Gerry Henningsen,
Director BAS Evansville -
Donnie A Evans,
Vice President Engineering -
Garyl W Doster,
Director -
Michael P Silvon,
Vice President -
Michael S Noone,
Dir. of Clinical Affairs, Balt -
William Sawyers,
Laboratory Director -
William D Pitchford,
Chief HR Officer